We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. OK, I agree | Cookies Policy

You are here

Magazine

8

New scientific communication on UTIPRO® PLUS

Following the publication of the experimental study by Fraile B et al. “Xyloglucan, hibiscus and propolis for the prevention of urinary tract infections: results of in vitro studies.” on Future Microbiology 2017; 12: 721-73, the authors presented a new communication at the VII International Congress of Histology and Tissue Engineering. Santiago de Compostela 5-8 Sept 2017. The results confirm the non-pharmacological barrier effect of xyloglucan and its utility in the prevention of urinary tract infections.

Read more

New scientific publication on RHINOSECTAN®

A new publication carried out in a nasal mucosa model demonstrates the barrier effect of Rhinosectan®, which confirms its utility in nasal respiratory diseases such as allergic rhinitis. Rhinosectan® is a Class I medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE, Noventure SL) De Servi B et al. Protective barrier properties of Rhinosectan® spray (containing xyloglucan) on an organotypic 3D airway tissue model (MucilAir): results of an in vitro study. Allergy Asthma Clin Immunol. 2017 Aug 10;13:37

Read more

Let's meet in..

2020, Sep 14

euroPLX 73 Vienna

Read more

2020, Oct 13

CPhI 2020

Read more

2020, Nov 18

EWMA 2020 VIRTUAL

Read more

2020, Nov 23

euroPLX 74 Athens

Read more